aspirin

ESC 2020 | Fibrilación auricular y control del ritmo ¿Una cuestión de tiempo?

ESC 2020 | Atrial Fibrillation and Rhythm Control: A Matter of Time?

Early rhythm control therapy in patients recently diagnosed with atrial fibrillation reduces the risk of cardiovascular events compared against the usual treatment of frequency control.&nbsp; These data come from the EAST-AFNET 4 trial recently presented at ESC 2020, simultaneously published in NEJM. These data suggest that we should offer patients early rhythm control therapy to<a href="https://solaci.org/en/2020/09/02/esc-2020-atrial-fibrillation-and-rhythm-control-a-matter-of-time/" title="Read more" >...</a>

Nuevo dispositivo para tener mayor protección en la angioplastia carotídea

Natural History of Severe and Asymptomatic Carotid Lesions

Deciding whether to intervene a severe (70-80%) carotid lesion in an asymptomatic patient is challenging. We know the margin of error is small and an excess of events caused by the intervention could tilt the scales. However, the updated information on the natural evolution of these lesions is scarce. This retrospective analysis included asymptomatic patients<a href="https://solaci.org/en/2020/08/21/natural-history-of-severe-and-asymptomatic-carotid-lesions/" title="Read more" >...</a>

La FDA aprueba el ticagrelor en pacientes de alto riesgo como prevención primaria

The FDA Approves Ticagrelor for Primary Prevention in High Risk Patients

The FDA has approved the indication of ticagrelor as primary prevention in high risk CAD patients with no history of MI or stroke.&nbsp; The lab producing ticagrelor has informed the FDA has based this decision on the THEMIS study, which included nearly 20,000 patients with stable CAD and type 2 diabetes. This decision has come<a href="https://solaci.org/en/2020/06/26/the-fda-approves-ticagrelor-for-primary-prevention-in-high-risk-patients/" title="Read more" >...</a>

Doctor con tabletas de aspirinas

Are Non-Culprit Lesions Really Innocent?

In recent times, a lot has been said about reducing the duration or intensity of antiplatelet therapy following percutaneous coronary intervention (PCI) regardless initial indications. All evidence in support of these arguments might be failing to show the risk of non-culprit lesion events in patients with acute coronary syndromes (ACS). Potent and prolonged antithrombotic therapies<a href="https://solaci.org/en/2020/04/22/are-non-culprit-lesions-really-innocent/" title="Read more" >...</a>

ACC Virtual 2020 | TICO: monoterapia de ticagrelor en síndromes coronarios agudos

Virtual ACC 2020 | TICO: Ticagrelor Monotherapy in Acute Coronary Syndromes

Switching to ticagrelor monotherapy after 3&nbsp;months of dual antiplatelet therapy reduces major bleeding without paying a price in terms of ischemic events, compared with dual antiplatelet therapy for a year, in patients who had acute coronary syndrome and underwent angioplasty with a second-generation drug-eluting stent. Interrupting aspirin at 3&nbsp;months and switching it for ticagrelor reduces<a href="https://solaci.org/en/2020/04/06/virtual-acc-2020-tico-ticagrelor-monotherapy-in-acute-coronary-syndromes/" title="Read more" >...</a>

Virtual ACC 2020 | TWILIGHT-COMPLEX: Ticagrelor Monotherapy in the Most “Dangerous” Angioplasties

The original TWILIGHT findings in more than 9000&nbsp;patients who underwent angioplasty were presented last year at TCT and showed a 3.1% absolute risk reduction in BARC&nbsp;2, 3, or 5 bleeding with no increase in death, infarction, or stroke in patients who received ticagrelor and placebo compared with patients who received ticagrelor and aspirin. All patients<a href="https://solaci.org/en/2020/04/02/virtual-acc-2020-twilight-complex-ticagrelor-monotherapy-in-the-most-dangerous-angioplasties/" title="Read more" >...</a>

Virtual ACC 2020 | TWILIGHT-DM: Ticagrelor Monotherapy in Diabetic Patients

In parallel to the TWILIGHT in patients with complex PCI, Dr. Angiolillo virtually presented the sub-study in diabetic patients, and it was published simultaneously in J Am Coll Cardiol. This study focuses on the clinical complexity of patients, rather than the technical complexity of the procedure itself.&nbsp; The TWILIGHT-DM analyzed 2620 diabetic patients from the<a href="https://solaci.org/en/2020/04/02/virtual-acc-2020-twilight-dm-ticagrelor-monotherapy-in-diabetic-patients/" title="Read more" >...</a>

ACC 2020 Virtual | Sub-análisis del COMPASS: la diabetes aumenta el beneficio del rivaroxaban más AAS

Virtual ACC 2020 | COMPASS Sub-Analysis: Diabetes Increases the Benefit of Rivaroxaban Combined with AAS

In patients with stable coronary or peripheral artery disease, diabetes increases the benefit of combining low doses of rivaroxaban and aspirin vs. aspirin alone.&nbsp; This analysis was pre-specified in the COMPASS protocol and was presented virtually for the ACC 2020 and simultaneously published in Circulation. Patients with diabetes, showed numerically greater reduction in terms of<a href="https://solaci.org/en/2020/03/30/virtual-acc-2020-compass-sub-analysis-diabetes-increases-the-benefit-of-rivaroxaban-combined-with-aas/" title="Read more" >...</a>

mas-leido-febrero-eng-420x283-compressor

The Most Read Scientific Articles of February

01- Alternatives for Patients Allergic to Aspirin The new guidelines of chronic coronary syndromes make class IIb recommendations to use prasugrel or ticagrelor in aspirin-intolerant patients. This is not meant to replace dual antiaggregation therapy in aspirin intolerant patients, when needed; it is just a recommendation to use monotherapy with the most potent antiaggregant we<a href="https://solaci.org/en/2020/03/11/the-most-read-scientific-articles-of-february/" title="Read more" >...</a>

Recomendaciones de la ACC con el nuevo coronavirus

ACC Recommendations against the New Coronavirus

The American College of Cardiology (ACC) has launched a document summarizing the potential implications of the new coronavirus identified in Wuhan, China. This new virus has been called COVID-19 by the WHO. According to the WHO reports, there are around 93000 confirmed cases across the world, and around 12600 are outside China. In Latin America,<a href="https://solaci.org/en/2020/03/04/acc-recommendations-against-the-new-coronavirus/" title="Read more" >...</a>

Top